Introduction
Guselkumab (GUS) markedly improved overall endoscopic outcomes in Crohn’s disease (CD), achieving high rates of endoscopic response and remission during its Phase 3 trial program.1,2 Disease location may represent a key determinant of treatment effectiveness, but data on segment-specific changes is still limited. We assessed ulcer size and percentage of ulcerated surface across bowel segments over 1 year in participants (pts) from the pooled GALAXI 2&3 trials.
Aims & Methods
Post-hoc analyses pooled data from Phase 3 GALAXI 2&3 trials in adults with moderately to severely active CD randomized to intravenous GUS 200mg at week (W) 0, W4, W8, followed by subcutaneous GUS 100mg every 8W (Q8W) from W16-40 or GUS 200mg Q4W from W12-44. Simple Endoscopic Score for CD (SES-CD) variables of ulcer size (none, aphthous [0.1-0.5cm], large [0.5-2cm], very large [>2cm]) and ulcerated surface (none, <10%, 10-30%, >30%) were assessed by central reading at W0, W12, and W48. Within-bowel segment (ileum, right colon, transverse colon, left colon/sigmoid colon, rectum) changes over time were analysed as observed using the Wilcoxon signed-rank test. All p-values are nominal.
Results
In total, 582 GUS-treated pts were included: 57% males; mean age=36.5 years; mean disease duration=7.1 years; mean W0 CD Activity Index score=296.1; mean W0 SES-CD score=12.8; 53% with ≥1 failed biologic therapy. At W0, a higher proportion of pts had ulcers in the ileum (74%) than in the colonic (39%) and rectal (50%) segments.
Among pts with ulcers within a given bowel segment at W0, GUS induction through W12 significantly reduced ulcer size irrespective of the segment (all p<0.0001 vs W0; Table 1). These reductions were further enhanced and sustained through W48 with GUS maintenance (all p<0.0001 vs W0 and vs W12; Table 1). Greater reductions in ulcer size were observed in colonic and rectal segments than in the ileum at W12 and W48; reductions in very large ulcers were comparable across segments (Table 1). Similar findings were observed for the percentage of ulcerated surface across all bowel segments (all p<0.0001 for W12 vs W0, W48 vs W0, W48 vs W12).
Table 1. Distribution of ulcer size by bowel segment at W0, W12 and W48 in pts with ulcers within a given bowel segment at W0
| Bowel Segment | Parameter | Level | W0 | W12 | W48 |
Ileum (N=354) | Presence/Size | None Aphthous [0.1-0.5cm] Large [0.5-2cm] Very large [> 2cm] | - 30% 39% 31% | 25% 29% 29% 17% | 37% 29% 26% 8% |
Right colon (N=261) | Presence/Size | None Aphthous [0.1-0.5cm] Large [0.5-2cm] Very large [> 2cm] | - 45% 35% 20% | 55% 21% 19% 5% | 67% 16% 13% 3% |
Transverse colon (N=219) | Presence/Size | None Aphthous [0.1-0.5cm] Large [0.5-2cm] Very large [> 2cm] | - 48% 24% 28% | 56% 24% 12% 8% | 78% 11% 9% 3% |
Left colon/sigmoid (N=296) | Presence/Size | None Aphthous [0.1-0.5cm] Large [0.5-2cm] Very large [> 2cm] | - 48% 20% 33% | 47% 26% 9% 17% | 69% 15% 11% 5% |
Rectum (N=288) | Presence/Size | None Aphthous [0.1-0.5cm] Large [0.5-2cm] Very large [> 2cm] | - 49% 25% 26% | 48% 27% 15% 10% | 66% 19% 10% 6% |
Conclusion
Among adults with moderately to severely active CD in GALAXI 2&3, GUS markedly reduced ulcer size and percentage of ulcerated surface across all bowel segments as early as W12, with effects sustained through W48. These findings suggest early and durable endoscopic improvement with GUS.
References
- Hart A et al. Gastroenterology. 2025;169:308-325.
- Panaccione R et al. Lancet. 2025;406:358-375.
Disclosure
AA: Consulting fees: AbbVie, Abivax, Alfa Sigma, Astra Zeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Eli Lilly, Enthera, Ferring, Galapagos, Gilead, Giuliani, Johnson & Johnson, Lionhealth, MSD, Nestlé, Pfizer, Protagonist Therapeutics, Roche, Samsung Bioepis, Sanofi, Sandoz, Takeda, Teva Pharmaceuticals, and Tillots Pharma; Speaker’s fees: AbbVie, Abivax, AG Pharma, Alfa Sigma, Biogen, Bristol-Myers Squibb, Celltrion, Eli Lilly, Ferring, Galapagos, Gilead, Johnson & Johnson, Lionhealth, MSD, Novartis, Pfizer, Roche, Samsung Bioepis, Sandoz, Takeda, Teva Pharmaceuticals; Research support: Biogen, MSD, Takeda, and Pfizer; Non-financial support: AbbVie, Johnson & Johnson, MSD, Pfizer, and Takeda.
MFu: Grant: Pfizer; Personal Fees: Abbvie, Amgen, Arena, Biogen, Boehringer, Celgene, CTMA, Eli Lilly, Ferring, Fresenius, Galapagos, Gilead, Hospira, Johnson & Johnson, MSD, Mylan, Pfizer, Sandoz, Takeda, and Tillots; Non-financial Support: AbbVie, Ferring, Galapagos, Johnson & Johnson, MSD, Pfizer, and Takeda.
BES: Consulting fees:Abbvie, Adiso Therapeutics, Agomab, Alimentiv , Amgen, AnaptysBio, Arena Pharmaceuticals, Artugen Therapeutics, Astra Zeneca, Biolojic Design, Biora Therapeutics, Boehringer Ingelheim, Boston Pharmaceuticals, Calibr, Celgene, Celltrion, ClostraBio, Equillium, Enthera, Enveda Biosciences, Evommune, Ferring, Fresenius Kabi, Fzatat, Galapagos, Genentech (Roche), Gilead, GlaxoSmithKline, Gossamer Bio, Imhotex, Index Pharmaceuticals, Innovation Pharmaceuticals, Inotrem, Kaleido, Kallyope, Merck, Microba, Mobius Care, Morphic Therapeutics, MRM Health, Nexus Therapeutics, Nimbus Discovery, Odyssey Therapeutics, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Q32Bio, Rasayana Therapeutics, Recludix Therapeutics, Reistone Biopharma, Sanofi, Spyre Therapeutics, Sun Pharma, Surrozen, Target RWE,Teva, TLL Pharmaceutical, Tr1X, Union Therapeutics, Ventyx Biosciences; Consulting and speaking fees from Abivax; Consulting and speaking fees and other support from Eli Lilly; Research grants, consulting and speaking fees and other support: Bristol Myers Squibb, Johnson & Johnson, Pfizer, Takeda; research grants and consulting fees from Theravance Biopharma; and stock/stock options from Ventyx Biopharma.
MFe: Research grants: AbbVie, EG Pharma, Celltrion, Johnson & Johnson, Pfizer, Takeda and Viatris; Consultancy fees: AbbVie, AgomAb Therapeutics, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Johnson & Johnson, MRM Health, MSD, Pfizer, Takeda, and ThermoFisher; Speakers’ fees: AbbVie, Biogen, Boehringer Ingelheim, Dr Falk Pharma, Ferring, Johnson & Johnson, Merck Sharp and Dohme, Pfizer, Takeda, Truvion Healthcare, and Viatris.
TR: research and educational grants and/or speaker/consultation fees: Abbvie, Alfasigma, Arena, Aslan, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Domain Therapeutics, Eli Lilly, Ferring, Galapagos, Gilead, GlaxoSmithKline, Heptares, Johnson & Johnson, LabGenius, MonteRosa, Mylan, Merck Sharpe & Dohme, Novartis, Numab, Pfizer, Roche, Sandoz, Scientia, Takeda, UCB, and XAP therapeutics.
RVR, MN, JVD, VM: Employee: Johnson & Johnson; may own/owns stocks in Johnson & Johnson.
RA: Speaker, consultant, or received research grants: AbbVie, Abivax, AlfaSigma, Arena Pharmaceuticals, Astra-Zeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion Healthcare, Dr Falk Pharma, Galapagos, Gilead, GlaxoSmithKline, InDex Pharmaceuticals, Johnson & Johnson, Eli Lilly, Materia Prima, Merck Sharpe & Dohme, Pfizer, Roche Pharma, Takeda Pharma, and Viatris.